Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

Video

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma. 

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
A panel of 3 experts on GVHD
A panel of 3 experts on GVHD
Related Content
Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

April 11th 2024
Article

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

April 10th 2024
Article

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Read More

Targeting Multiple Myeloma With the Latest Therapies

Targeting Multiple Myeloma With the Latest Therapies

April 9th 2024
Article

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Read More